Wave Life Sciences Ltd. - Ordinary Shares (WVE): Price and Financial Metrics


Wave Life Sciences Ltd. - Ordinary Shares (WVE): $7.24

-0.23 (-3.08%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

WVE POWR Grades


  • WVE scores best on the Growth dimension, with a Growth rank ahead of 55.84% of US stocks.
  • The strongest trend for WVE is in Momentum, which has been heading down over the past 31 weeks.
  • WVE ranks lowest in Momentum; there it ranks in the 5th percentile.

WVE Stock Summary

  • Of note is the ratio of Wave Life Sciences Ltd's sales and general administrative expense to its total operating expenses; just 11.86% of US stocks have a lower such ratio.
  • With a price/sales ratio of 21.21, Wave Life Sciences Ltd has a higher such ratio than 90.62% of stocks in our set.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for WVE comes in at -48.16% -- higher than that of only 5.12% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Wave Life Sciences Ltd, a group of peers worth examining would be CTMX, PIRS, MRUS, DTIL, and MCRB.
  • WVE's SEC filings can be seen here. And to visit Wave Life Sciences Ltd's official web site, go to www.wavelifesciences.com.

WVE Price Target

For more insight on analysts targets of WVE, see our WVE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $9.00 Average Broker Recommendation 1.64 (Moderate Buy)

WVE Stock Price Chart Interactive Chart >

Price chart for WVE

WVE Price/Volume Stats

Current price $7.24 52-week high $19.98
Prev. close $7.47 52-week low $4.82
Day low $7.06 Volume 766,900
Day high $7.55 Avg. volume 828,762
50-day MA $6.41 Dividend yield N/A
200-day MA $8.83 Market Cap 360.96M

Wave Life Sciences Ltd. - Ordinary Shares (WVE) Company Bio


WAVE Life Sciences Pte. Ltd., a preclinical biopharmaceutical company, designs, develops, and commercializes nucleic acid therapeutic candidates. The company was founded in 2012 and is based in Simgapore.


WVE Latest News Stream


Event/Time News Detail
Loading, please wait...

WVE Latest Social Stream


Loading social stream, please wait...

View Full WVE Social Stream

Latest WVE News From Around the Web

Below are the latest news stories about Wave Life Sciences Ltd that investors may wish to consider to help them evaluate WVE as an investment opportunity.

Wave Life Sciences' RNA Editing Platform Shows Restoration of Functional AAT Protein in Preclinical Study

Wave Life Sciences Ltd (NASDAQ: WVE) has announced the first proof-of-concept preclinical data for its ADAR (adenosine deaminases acting on RNA)-mediated RNA editing program in alpha-1 antitrypsin deficiency (AATD). AATD is a genetic disorder that may result in lung disease or liver disease. Up to 40% editing of human SERPINA1 Z-allele mRNA in the liver was observed at a single time point, which resulted in a therapeutically meaningful increase in circulating functional wild-type AAT protein. Ed

Yahoo | June 3, 2021

Wave Life Sciences Announces Proof-of-Concept Preclinical Data for ADAR Editing Program in Alpha-1 Antitrypsin Deficiency

First proof-of-concept in vivo data for RNA editing using endogenous ADAR enzymes in alpha-1 antitrypsin deficiency ADAR editing resulted in therapeutically meaningful restoration of circulating functional AAT protein Wave’s program in alpha-1 antitrypsin deficiency aims to correct the single base mutation in mRNA derived from the SERPINA1 Z allele, thereby addressing both lung and liver manifestations of the disease CAMBRIDGE, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Na

Yahoo | June 2, 2021

Wave Life Sciences (WVE) Investor Presentation - Slideshow

The following slide deck was published by Wave Life Sciences Ltd. in conjunction with this event....

SA Transcripts on Seeking Alpha | May 21, 2021

Wave Life Sciences Ltd. 2021 Q1 - Results - Earnings Call Presentation

The following slide deck was published by Wave Life Sciences Ltd. in conjunction with their 2021 Q1 earnings call....

SA Transcripts on Seeking Alpha | May 13, 2021

Wave Life Sciences (WVE) Reports Q1 Loss, Misses Revenue Estimates

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -53.57% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | May 13, 2021

Read More 'WVE' Stories Here

WVE Price Returns

1-mo 16.59%
3-mo -27.74%
6-mo -21.13%
1-year -24.82%
3-year -85.21%
5-year -55.11%
YTD -8.01%
2020 -1.81%
2019 -80.93%
2018 19.77%
2017 34.23%
2016 63.95%

Continue Researching WVE

Want to see what other sources are saying about Wave Life Sciences Ltd's financials and stock price? Try the links below:

Wave Life Sciences Ltd (WVE) Stock Price | Nasdaq
Wave Life Sciences Ltd (WVE) Stock Quote, History and News - Yahoo Finance
Wave Life Sciences Ltd (WVE) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.1578 seconds.